{"product_id":"dxcm-marketing-mix","title":"DexCom, Inc. (DXCM): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Marketing Mix Analysis of DexCom, Inc. Business as of late 2025 gives you a practical, research-based view of how the company sells continuous glucose monitoring systems across prescription and OTC channels, with coverage of product strategy, U.S. and international distribution, promotion, pricing, customer segments, and brand positioning. You’ll see how G7 15 Day, Stelo, and glucose-data apps shape the offering, how the U.S. market reached \u003cstrong\u003e$3.38B\u003c\/strong\u003e in revenue versus \u003cstrong\u003e$1.28B\u003c\/strong\u003e internationally, how Stelo opened an OTC consumer channel for non-insulin-using adults, and how pricing such as \u003cstrong\u003e$99\u003c\/strong\u003e for two sensors and \u003cstrong\u003e$89\u003c\/strong\u003e monthly subscription supports consumer access and market reach.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eDexCom, Inc. - Marketing Mix: Product\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eDexCom, Inc.\u003c\/strong\u003e builds its product mix around continuous glucose monitoring, or CGM, hardware and software. In late 2025, the core product set centered on the \u003cstrong\u003eG7 15 Day CGM\u003c\/strong\u003e, the \u003cstrong\u003eStelo\u003c\/strong\u003e over-the-counter glucose sensor, and glucose-data apps that turn sensor readings into usable health information.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eProduct\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eCustomer group\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eKey product feature\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eReal-life number\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eG7 15 Day CGM\u003c\/td\u003e\n    \u003ctd\u003ePeople using CGM for glucose management\u003c\/td\u003e\n    \u003ctd\u003eExtended wear sensor\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e15.5 days\u003c\/strong\u003e of wear\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eStelo\u003c\/td\u003e\n    \u003ctd\u003eNon-insulin-using adults\u003c\/td\u003e\n    \u003ctd\u003eFirst FDA-cleared OTC glucose sensor\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003eOver-the-counter\u003c\/strong\u003e status\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGlucose-data apps\u003c\/td\u003e\n    \u003ctd\u003eUsers and care teams\u003c\/td\u003e\n    \u003ctd\u003eData display, trends, and insights\u003c\/td\u003e\n    \u003ctd\u003eConnected to CGM sensor data\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eG7 15 Day CGM\u003c\/strong\u003e became the main product extension in the U.S. because it increased wear time to \u003cstrong\u003e15.5 days\u003c\/strong\u003e. That matters because longer wear reduces how often a user changes sensors, lowers disruption, and makes the device easier to use in daily life. For a CGM company, wear duration is a direct product advantage because it affects convenience, adherence, and repeat use.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStelo\u003c\/strong\u003e is the first \u003cstrong\u003eFDA-cleared OTC glucose sensor\u003c\/strong\u003e. OTC means over the counter, so customers do not need a prescription. That product design expands the market beyond traditional insulin-treated patients and makes glucose sensing accessible to a wider adult audience. The product is aimed at \u003cstrong\u003enon-insulin-using adults\u003c\/strong\u003e, which gives DexCom, Inc. a separate consumer-style product line instead of relying only on clinical prescribing channels.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003eG7 15 Day CGM\u003c\/strong\u003e: focuses on longer wear time and lower user friction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStelo\u003c\/strong\u003e: focuses on direct consumer access without a prescription.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGlucose-data apps\u003c\/strong\u003e: turn sensor readings into trends, alerts, and visual data.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSensor hardware\u003c\/strong\u003e: the physical product is the main revenue-linked asset.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe product architecture is not just a sensor. It combines \u003cstrong\u003ehardware\u003c\/strong\u003e and \u003cstrong\u003esoftware\u003c\/strong\u003e. The hardware collects glucose readings, while the apps display the information in a way that users and care teams can understand. In marketing mix terms, that makes the product a bundled offering: the device captures data, and the app increases the value of that data.\u003c\/p\u003e\n\n\u003cp\u003eDexCom, Inc. also uses product differentiation through access models. The \u003cstrong\u003eprescription-based CGM model\u003c\/strong\u003e serves users who need clinical monitoring, while \u003cstrong\u003eOTC access\u003c\/strong\u003e through Stelo serves adults who want glucose insights without going through a doctor first. That split matters because it broadens the addressable customer base and reduces dependence on one user segment.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eProduct element\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eDexCom, Inc. application\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDesign\u003c\/td\u003e\n    \u003ctd\u003eWearable sensor paired with digital app support\u003c\/td\u003e\n    \u003ctd\u003eImproves daily usability\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFeature set\u003c\/td\u003e\n    \u003ctd\u003eExtended wear, data tracking, glucose insights\u003c\/td\u003e\n    \u003ctd\u003eCreates product differentiation\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAccess model\u003c\/td\u003e\n    \u003ctd\u003ePrescription and OTC\u003c\/td\u003e\n    \u003ctd\u003eExpands customer reach\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality focus\u003c\/td\u003e\n    \u003ctd\u003eMedical-grade glucose monitoring\u003c\/td\u003e\n    \u003ctd\u003eSupports trust and repeat use\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor academic analysis, the key product point is that DexCom, Inc. sells a \u003cstrong\u003esensor-led ecosystem\u003c\/strong\u003e, not just a single device. The sensor creates the core utility, and the software increases the usefulness of each reading. That structure strengthens the product because it gives customers both measurement and interpretation in one system.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e15.5 days\u003c\/strong\u003e of wear increases convenience.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFDA-cleared OTC\u003c\/strong\u003e access lowers purchase friction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-insulin-using adults\u003c\/strong\u003e opens a larger consumer segment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSensor hardware plus apps\u003c\/strong\u003e creates a connected product system.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAs of late 2025, the product mix shows a clear move from a single clinical device toward a wider platform built around \u003cstrong\u003eCGM sensors, data apps, and direct consumer access\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eDexCom, Inc. - Marketing Mix: Place\u003c\/h2\u003e\n\n\u003cp\u003eDexCom’s place strategy is built around a two-region model: the U.S. is its largest market, and international revenue reached \u003cstrong\u003e$1.28B\u003c\/strong\u003e in 2025. U.S. revenue reached \u003cstrong\u003e$3.38B\u003c\/strong\u003e, which is \u003cstrong\u003e72.5%\u003c\/strong\u003e of the combined \u003cstrong\u003e$4.66B\u003c\/strong\u003e from these two regions.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRegion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2025 revenue\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eShare of U.S. + international revenue\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eU.S.\u003c\/td\u003e\n    \u003ctd\u003e$3.38B\u003c\/td\u003e\n    \u003ctd\u003e72.5%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInternational\u003c\/td\u003e\n    \u003ctd\u003e$1.28B\u003c\/td\u003e\n    \u003ctd\u003e27.5%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal\u003c\/td\u003e\n    \u003ctd\u003e$4.66B\u003c\/td\u003e\n    \u003ctd\u003e100.0%\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe U.S. scale matters because it gives DexCom the deepest commercial footprint, the largest installed base, and the strongest leverage with channel partners that matter in continuous glucose monitoring, or CGM, which means real-time glucose sensing outside a lab setting.\u003c\/p\u003e\n\n\u003cp\u003eDexCom serves the global CGM market, so its place strategy has to cover both domestic access and cross-border availability. That means the company has to make its products available through the right channels, in the right markets, and with enough inventory to support repeat use, since CGM is a recurring-use product rather than a one-time sale.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eU.S. market focus:\u003c\/strong\u003e $3.38B in 2025 revenue shows that domestic distribution remains the core of the business.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInternational reach:\u003c\/strong\u003e $1.28B in 2025 revenue shows that DexCom has a meaningful non-U.S. distribution base.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChannel access:\u003c\/strong\u003e CGM products must be available where patients fill prescriptions and where providers can support adoption.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRepeat availability:\u003c\/strong\u003e CGM users need continuous supply, so inventory planning matters more than for a one-off device sale.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProduct availability:\u003c\/strong\u003e The U.S. launch of G7 15 Day adds another availability point inside DexCom’s domestic channel mix.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe launch of G7 15 Day in the United States is important for place because distribution is not only about geography. It is also about how many versions of a product are available in a market and how quickly patients and providers can access them.\u003c\/p\u003e\n\n\u003cp\u003eFor DexCom, place is closely tied to prescription-driven access, payer acceptance, and fulfillment reliability. In CGM, the product must be easy to obtain, refill, and replace because patients use sensors on a recurring cycle. That makes channel execution a direct driver of revenue retention.\u003c\/p\u003e\n\n\u003cp\u003eU.S. revenue of \u003cstrong\u003e$3.38B\u003c\/strong\u003e versus international revenue of \u003cstrong\u003e$1.28B\u003c\/strong\u003e also shows that DexCom’s distribution footprint is still more concentrated in the U.S. than abroad. That concentration matters because it makes the company more dependent on U.S. channel performance, reimbursement access, and provider adoption.\u003c\/p\u003e\n\n\u003cp\u003eDexCom’s global CGM position means place is not limited to physical shipment. It also includes how the company supports healthcare providers, pharmacies, distributors, and end users across multiple countries so the device is accessible when prescribed and usable throughout the sensor life cycle.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003ePlace factor\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eDexCom implication\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eU.S. distribution depth\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$3.38B\u003c\/strong\u003e in 2025 revenue shows the U.S. is the main access and fulfillment market.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInternational expansion\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$1.28B\u003c\/strong\u003e in 2025 revenue shows broad access outside the U.S.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct availability\u003c\/td\u003e\n    \u003ctd\u003eG7 15 Day launched in the United States, expanding domestic choice and access.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRecurring supply\u003c\/td\u003e\n    \u003ctd\u003eCGM requires steady replenishment, so distribution continuity is essential.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGlobal reach\u003c\/td\u003e\n    \u003ctd\u003eDexCom serves the global CGM market, so distribution must work across multiple healthcare systems.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eDexCom, Inc. - Marketing Mix: Promotion\u003c\/h2\u003e\n\n\u003cp\u003eDexCom, Inc. uses promotion to widen awareness beyond intensive insulin users and to position continuous glucose monitoring as a broader daily health tool. The key promotional shift in late 2025 is the move from a prescription-only diabetes message to a wider consumer and wellness message through Stelo, G7 15 Day, and the Oura integration.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStelo\u003c\/strong\u003e opened an over-the-counter channel in the United States for adults \u003cstrong\u003e18+\u003c\/strong\u003e who do not use insulin. That matters because it changes promotion from physician-led education to consumer-facing demand generation, where awareness, app experience, and lifestyle messaging become more important than clinic adoption alone.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003ePromotion lever\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eReal-life fact\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eMarketing effect\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eStelo\u003c\/td\u003e\n    \u003ctd\u003eOver-the-counter launch for adults \u003cstrong\u003e18+\u003c\/strong\u003e who do not use insulin\u003c\/td\u003e\n    \u003ctd\u003eExpanded DexCom from prescription promotion to direct consumer awareness\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eG7 15 Day\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e15.5 days\u003c\/strong\u003e of wear time\u003c\/td\u003e\n    \u003ctd\u003eLonger wear time supports the message of convenience and lower replacement frequency\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOura integration\u003c\/td\u003e\n    \u003ctd\u003eConnected glucose data with wellness data in the Oura ecosystem\u003c\/td\u003e\n    \u003ctd\u003ePositioned DexCom in a broader health and wellness conversation\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eClinical evidence\u003c\/td\u003e\n    \u003ctd\u003eProduct claims are supported by published and regulatory-backed performance data\u003c\/td\u003e\n    \u003ctd\u003eImproves credibility and reduces adoption barriers\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eStelo launch opened an OTC consumer channel.\u003c\/strong\u003e That is a major promotional change because the target buyer is no longer only the clinician, educator, or payer. The consumer can discover the product directly, compare it with other health tools, and decide whether to buy without a prescription. For academic analysis, this is a clean example of channel expansion through promotion: the same core sensing capability is communicated through a different buyer journey.\u003c\/p\u003e\n\n\u003cp\u003eThe OTC approach also broadens messaging from medical necessity to everyday insight. For adults with prediabetes or type 2 diabetes not using insulin, the promotional emphasis shifts to glucose awareness, behavior tracking, and personal health management. That makes education content, app onboarding, digital media, and search-driven discovery more important than hospital detail alone.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eTarget group expanded to adults \u003cstrong\u003e18+\u003c\/strong\u003e not using insulin\u003c\/li\u003e\n  \u003cli\u003ePurchase path shifted from prescription to OTC\u003c\/li\u003e\n  \u003cli\u003ePromotion moved closer to consumer education and digital discovery\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eG7 15 Day marketing highlights longer wear time.\u003c\/strong\u003e The key number is \u003cstrong\u003e15.5 days\u003c\/strong\u003e, which is longer than the previous 10-day wear model. In promotional terms, that number is simple, memorable, and commercially relevant because it speaks directly to convenience. Fewer sensor changes can reduce friction in day-to-day use, and promotion can focus on that practical benefit rather than on technical specifications alone.\u003c\/p\u003e\n\n\u003cp\u003eThe longer wear message also helps DexCom compete on total user experience. A sensor that lasts \u003cstrong\u003e15.5 days\u003c\/strong\u003e can be framed as less disruptive, more efficient, and better suited for people who want continuous data without frequent replacement. In a marketing mix context, this is a product feature that becomes a promotion headline.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eWear time: \u003cstrong\u003e15.5 days\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003ePromotional message: longer wear, less interruption, easier routine\u003c\/li\u003e\n  \u003cli\u003eConsumer value: fewer changes over the same time period\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOura integration linked glucose and wellness data.\u003c\/strong\u003e This matters because it places DexCom inside a broader wellness narrative, not just a diabetes management narrative. The promotional value comes from cross-platform visibility: glucose data can be interpreted alongside sleep, readiness, activity, and other wellness inputs. That makes the product relevant to consumers who track health metrics continuously and want a single view of their body data.\u003c\/p\u003e\n\n\u003cp\u003eFor DexCom, this kind of integration supports brand positioning in the digital health category. It helps the company speak to users who may not identify first as diabetes patients but do identify as health trackers. In academic writing, this is a strong example of how partnerships can extend promotion without changing the core product.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eIntegration element\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003ePromotion value\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGlucose data\u003c\/td\u003e\n    \u003ctd\u003eShows real-time metabolic information\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eWellness data\u003c\/td\u003e\n    \u003ctd\u003ePlaces glucose in a broader lifestyle context\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eConsumer app ecosystem\u003c\/td\u003e\n    \u003ctd\u003eIncreases engagement through daily use\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eBrand messaging expanded beyond insulin users.\u003c\/strong\u003e That is one of the most important promotional shifts for DexCom. The company’s audience now includes people with prediabetes, type 2 diabetes not using insulin, and consumers interested in metabolic health. This widens the top of the funnel, meaning more people can be reached before they ever enter a clinical pathway.\u003c\/p\u003e\n\n\u003cp\u003eThis broader message is commercially important because it changes the size and composition of the addressable audience. Instead of relying only on medically advanced users, the company can promote awareness earlier in the health journey. That can support stronger brand familiarity, more app downloads, and better conversion into paid use cases.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eTraditional audience: insulin users\u003c\/li\u003e\n  \u003cli\u003eExpanded audience: adults \u003cstrong\u003e18+\u003c\/strong\u003e not using insulin\u003c\/li\u003e\n  \u003cli\u003eMessaging shift: disease management plus wellness insight\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical evidence supports product adoption.\u003c\/strong\u003e DexCom’s promotion depends heavily on evidence because glucose monitoring is a medical product, not just a consumer gadget. Strong clinical evidence reduces skepticism, supports physician recommendations, and strengthens payer confidence. In practice, that means promotion is not only advertising; it is also evidence communication.\u003c\/p\u003e\n\n\u003cp\u003eFor academic use, the most important point is that DexCom’s promotional strategy combines consumer marketing with medical validation. The consumer message creates interest, while the clinical message lowers adoption risk. That balance is especially important for products that straddle healthcare and consumer wellness.\u003c\/p\u003e\n\n\u003cp\u003ePromotion in late 2025 can be organized as a three-part structure:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsumer access\u003c\/strong\u003e through Stelo’s OTC channel\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConvenience messaging\u003c\/strong\u003e through G7 15 Day’s \u003cstrong\u003e15.5-day\u003c\/strong\u003e wear time\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDigital ecosystem reach\u003c\/strong\u003e through the Oura integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe promotional mix also reflects a shift in messaging depth. DexCom is no longer promoting only glucose alerts and diabetes control. It is promoting convenience, lifestyle fit, and continuous insight. That makes the message more relevant to people who want health data they can use every day, not only during medical appointments.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003ePromotion theme\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eCore message\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eStrategic meaning\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAccess\u003c\/td\u003e\n    \u003ctd\u003eOTC availability\u003c\/td\u003e\n    \u003ctd\u003eLowered dependence on prescription-only promotion\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eConvenience\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e15.5 days\u003c\/strong\u003e wear time\u003c\/td\u003e\n    \u003ctd\u003eHighlighted ease of use\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eIntegration\u003c\/td\u003e\n    \u003ctd\u003eGlucose plus wellness data\u003c\/td\u003e\n    \u003ctd\u003eExpanded relevance beyond diabetes alone\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCredibility\u003c\/td\u003e\n    \u003ctd\u003eClinical evidence\u003c\/td\u003e\n    \u003ctd\u003eSupported trust and adoption\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eDexCom, Inc. - Marketing Mix: Price\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$99\u003c\/strong\u003e for \u003cstrong\u003e2 sensors\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$89\u003c\/strong\u003e monthly subscription pricing\u003c\/p\u003e\n\u003cp\u003eDirect-to-consumer pricing is publicly disclosed for \u003cstrong\u003eStelo\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eG7 15 Day\u003c\/strong\u003e public pricing was not disclosed here.\u003c\/p\u003e\n\u003cp\u003eThe publicly stated direct consumer price points are simple and transparent: \u003cstrong\u003e$99\u003c\/strong\u003e for \u003cstrong\u003e2 sensors\u003c\/strong\u003e and \u003cstrong\u003e$89\u003c\/strong\u003e per month for subscription pricing. That makes the consumer offer easy to compare against other medical technology purchases because the buyer sees an upfront out-of-pocket amount instead of a complex reimbursement structure.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct\u003c\/td\u003e\n    \u003ctd\u003ePublic price\u003c\/td\u003e\n    \u003ctd\u003eUnit basis\u003c\/td\u003e\n    \u003ctd\u003ePricing status\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eStelo\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$99\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2 sensors\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003ePublicly disclosed direct consumer price\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eStelo subscription\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$89\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eMonthly\u003c\/td\u003e\n    \u003ctd\u003ePublicly disclosed direct consumer price\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eG7 15 Day\u003c\/td\u003e\n    \u003ctd\u003eNot disclosed here\u003c\/td\u003e\n    \u003ctd\u003eNot disclosed here\u003c\/td\u003e\n    \u003ctd\u003ePublic pricing not disclosed here\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eOn a per-sensor basis, the disclosed Stelo package implies \u003cstrong\u003e$49.50\u003c\/strong\u003e per sensor when priced at \u003cstrong\u003e$99\u003c\/strong\u003e for \u003cstrong\u003e2 sensors\u003c\/strong\u003e. The monthly subscription price of \u003cstrong\u003e$89\u003c\/strong\u003e gives a repeat-purchase structure that can support recurring revenue, which is the money a company receives again and again from customers over time.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$99\u003c\/strong\u003e entry price for \u003cstrong\u003e2 sensors\u003c\/strong\u003e supports low-friction consumer adoption.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$89\u003c\/strong\u003e monthly subscription supports recurring billing.\u003c\/li\u003e\n  \u003cli\u003ePublic direct pricing reduces uncertainty for self-pay buyers.\u003c\/li\u003e\n  \u003cli\u003ePublic pricing visibility can make the product easier to compare in academic pricing analysis.\u003c\/li\u003e\n  \u003cli\u003eG7 15 Day public pricing was not disclosed here, so it should not be estimated.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe pricing structure matters because it shows a consumer-accessible model rather than a hospital-only or insurer-only model. A fixed price like \u003cstrong\u003e$99\u003c\/strong\u003e for \u003cstrong\u003e2 sensors\u003c\/strong\u003e signals simplicity, while \u003cstrong\u003e$89\u003c\/strong\u003e monthly pricing signals a subscription-based approach that can improve predictability for both the buyer and the company.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602214252693,"sku":"dxcm-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/dxcm-marketing-mix.png?v=1740166547","url":"https:\/\/dcf-model.com\/fr\/products\/dxcm-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}